Pilot study of recombinant human α-interferon for chronic type B hepatitis

摘要: Nine patients with chronic type B hepatitis were entered into a preliminary study of recombinant, human alpha-interferon therapy. Patients received one to four courses interferon, each consisting fixed dose 18, 36, 50, 68, or 100 million units given three times week for 2 wk. Side effects including fever, chills, fatigue, myalgias, headache, and neutropenia common especially severe higher doses. Serum virus DNA polymerase activity fell during therapy 15%-30% the pretreatment levels irrespective interferon dose, but rose initial level by 10 days after course ended. During follow-up, had sustained clinical remission in which DNA, polymerase, e antigen disappeared from serum amino-transferase activities normal. One patient became surface negative. We conclude that doses (50 68 units) have greater side than lower (18 36 units), without having any antiviral efficacy. Further studies should be directed at over longer periods.